Физиотенз is a prescription preparation commonly used to help manage conditions associated with systemic imbalance where therapeutic intervention may be required to ease pressure readings. Its core application is for managing Essential Hypertension in adults, a condition characterized by chronic high blood pressure.

“Sustained pressure management is considered relevant for supporting cardiovascular health and assisting with functional stability during symptomatic periods.”

The medication is generally used to help with achieving consistent blood pressure reduction in individuals with essential high blood pressure. It is generally applied in settings where supportive symptom management is appropriate for conditions such as essential hypertension, resistant hypertension, and hypertension complicated by metabolic disorders.

It is considered relevant when high blood pressure remains uncontrolled despite treatment with primary agents, and may be part of symptomatic management as an add-on therapy to stabilize readings. It is also relevant for easing symptoms in conditions where hypertension coexists with metabolic disorders, where it may assist with supporting an improvement in metabolic markers alongside pressure management.

---

Key Information: Supporting Management of Elevated Blood Pressure

The medication helps address symptom clusters that may create noticeable physiological strain by contributing to consistent pressure management and easing the overall symptom burden of chronic hypertension.

---

Eligibility Profile for Физиотенз (Moxonidine)

The eligibility to use Физиотенз is strictly governed by contraindications and special restrictions outlined in official regulatory documents. This medicine is primarily intended for adults who do not have specific pre-existing conditions.

Absolute Contraindications (Must Not Use)

Condition / Population	Restriction
Heart Failure (cardiac insufficiency)	Absolute Prohibition
Severe Bradycardia (HR < 50 bpm)	Absolute Prohibition
2nd or 3rd Degree AV Block	Absolute Prohibition
Severe Renal Impairment (GFR < 30 mL/min)	Absolute Prohibition
Children and Adolescents (under 16)	Not Recommended / Not Established

Restricted or Conditional Use

The use of Moxonidine is not recommended during Pregnancy or Breastfeeding; if therapy is necessary during lactation, breastfeeding must be stopped. Caution and dose adjustment are required for patients with Moderate Renal Impairment (GFR 30 to < 60 mL/min) and those with First Degree AV Block. The medicine is also not recommended in elderly patients aged 75 years or older in some jurisdictions and should be avoided in patients with conditions like Parkinson's disease or a history of angioedema due to insufficient therapeutic experience.

Interaction Map: Interactions with other medicines and products — official regulatory information for Физиотенз (Moxonidine)

---

Interaction scope

Category	Official Regulatory Documentation
Medicinal product categories with documented interactions:	Other Antihypertensive medicinal products; Central Nervous System (CNS) Depressants (e.g., tranquilizers, sedatives, hypnotics); Agents excreted through tubular excretion.
Specific interacting medicines (if explicitly listed):	Tricyclic Anti-depressants (TCAs), Lorazepam, Beta-blockers (for discontinuation).
Mechanistic basis of interactions (only if stated in label):	Pharmacodynamic potentiation of sedation and additive hypotensive effects. Potential for reduced therapeutic efficacy (with TCAs) and potential interaction due to tubular excretion.
Timing-based interaction rules (if applicable):	If co-therapy with a Beta-blocker is ceased, the Beta-blocker must be discontinued first, and Moxonidine stopped after a few days.
Population-specific interaction notes (if applicable):	Patients with moderately impaired renal function require close monitoring due to official daily dose restrictions.
Interaction-related restrictions:	Tricyclic Anti-depressants are not recommended for co-administration. Alcohol can potentiate the sedative effect.

---

Interaction classifications (high-level)

Category	Classification Details
Interaction severity classification (as defined in official documents):	Combinations "not recommended" (TCAs); Combinations requiring procedural guidance (Beta-blockers); Clinically significant potentiation (CNS depressants, Alcohol).
Regulatory basis (EMA / FDA / etc.):	Summary of Product Characteristics (SmPC) from European national health agencies.
Interaction-context constraints (as defined in official documents):	Food intake has no effect on the pharmacokinetics, permitting administration regardless of meals.

---

Resulting interaction structure

Official interaction statements:

• Co-administration with other antihypertensive medicinal products results in an additive effect on blood pressure reduction.
• Moxonidine can potentiate the sedative effect of CNS Depressants, including alcohol, Tranquillisers, Sedatives, and Hypnotics.
• Co-administration with Tricyclic Anti-depressants is not recommended due to the potential for reduced efficacy.

Connection to the overall interaction profile (2–4 sentences): The official regulatory documents define the product's interaction profile primarily by pharmacodynamic potentiation, citing additive effects on blood pressure and sedation with other CNS agents. The profile includes a specific restriction against Tricyclic Anti-depressants based on the risk of efficacy reduction, and a mandatory procedural requirement regarding the sequence for discontinuing beta-blockers.

How Физиотенз Works: Mechanism of Action

Физиотенз (Moxonidine) operates as a selective agonist for Imidazoline I1 receptors, primarily localized in the rostral ventrolateral medulla (RVLM) of the brainstem. Activation of these central I1 receptors initiates a signaling cascade that dampens the overall central Sympathetic Nervous System (SNS) outflow to the peripheral organs. This systemic reduction in sympathetic nerve activity decreases the release of circulating catecholamines at peripheral nerve endings.

The resulting physiological consequence is the relaxation of vascular smooth muscle, which directly decreases systemic vascular resistance. Reduced resistance results in a lowered arterial blood pressure. Furthermore, the central action indirectly modulates the Renin-Angiotensin-Aldosterone System (RAAS) by reducing renin release from the kidneys, promoting natriuresis. A secondary mechanism involves the modulation of pathways affecting insulin sensitivity in peripheral tissues, which influences metabolic state alongside cardiovascular regulation.

The administration of Физиотенз (Moxonidine) follows an established protocol for the initiation, adjustment, and cessation of treatment.

Administration and Dosing Schedule

The medicine is formulated exclusively as a film-coated tablet for oral administration. Tablets must be swallowed whole with sufficient fluid and should not be chewed or crushed. Administration is flexible and can occur with or without food.

Treatment is typically initiated with a starting dose of 200 mu g once daily, usually taken in the morning. Dose adjustments, if required, are made in 200 mu g increments only after a minimum interval of two to three weeks if the clinical response is judged insufficient. The maximum dose for any single intake is 400 mu g, and the total daily intake must not exceed 600 mu g. When the total daily dose is 400 mu g or more, the total amount is generally divided into two separate doses taken in the morning and evening.

Special Procedural Requirements

For patients with renal impairment, a maximum daily dose is mandated to be reduced (e.g., 400 mu g or 300 mu g, depending on severity), with a single dose limit of 200 mu g. The medicine is generally not recommended for individuals under 16 years of age. If a dose is missed, the patient should proceed with the next scheduled dose at the regular time and should not take a double dose to compensate. Final discontinuation of the medicine requires the dosage to be gradually reduced over a period of approximately two weeks.

Research evidence / Overview of studies for Физиотенз (Moxonidine)

Evidence for use in Essential Hypertension

This section will summarize the structure of the foundational clinical research, primarily focusing on the short-term Randomized Controlled Trials (RCTs) that examined changes in blood pressure readings and ambulatory monitoring parameters in adults with mild to moderate high blood pressure.

Research into how Физиотенз (Moxonidine) was studied was initially centered on short-term Randomized Controlled Trials (RCTs). These studies were generally designed to measure parameters related to physical discomfort and physiological strain, specifically looking at changes in blood pressure. The main research approach examined parameters related to systemic or functional imbalance in adults with mild to moderate essential hypertension.

These trials reported how symptoms evolved in the observed populations by documenting changes in Systolic and Diastolic Blood Pressure (BP), both during clinic visits and through 24-hour Ambulatory Blood Pressure Monitoring (ABPM). Research described patterns observed when the medication was used alone or alongside other study treatments. These findings describe patterns related to short-term changes in blood pressure over periods lasting a few weeks to a few months.

Research in Complex Hypertension and Metabolic Conditions

This part will outline the studies that explored the use of Физиотенз in patients where high blood pressure coexists with metabolic conditions like obesity or metabolic syndrome, detailing the trials that looked at metabolic markers and the patterns of research reported in these complex groups.

Research explored the use of Физиотенз in populations where high blood pressure coexists with conditions such as Metabolic Syndrome or Obesity. The study parameters examined included changes in blood pressure but also monitored metabolic markers related to systemic imbalance, such as measures of Insulin Resistance and blood lipid levels. Findings were mixed across these studies, and the changes in metabolic markers were often tracked as secondary, rather than primary, parameters.

Long-term Research and Durability of Study Findings

When considering the long-term evidence, it is important to note that the majority of the data available for this medication is from studies that had limited follow-up durations, typically only a few months. Evidence for the long-term effects of the medication on critical health endpoints like the prevention of major cardiovascular events remains limited.

Understanding Research Gaps and Uncertainty

This section will synthesize the main areas where scientific insight remains limited, including key research uncertainties and data limitations noted by regulatory reviewers and in peer-reviewed meta-analyses.

The most significant research gap is the limited information for long-term outcomes on major cardiovascular events, which is a key research focus for fully characterizing antihypertensive therapy. Additionally, comparative evidence is lacking for many subgroup findings, and the results apply only to the populations studied, meaning that more dedicated research is ongoing to fully understand the medication's research profile across all patient demographics and over extended periods.

Key Studies & References Public Assessment Report Decentralised Procedure: Moxonidine

Common questions about Физиотенз (FAQ)

---

Q: What should I do if I forget to take a dose?

If a dose is missed, official product information states that proceeding with the next scheduled dose at the regular time is the recommended course. The labeling specifies that a double dose should not be taken to compensate for a forgotten dose.

---

Q: What is the proper procedure for discontinuing treatment with a Beta-blocker?

Regulatory documents provide procedural guidance regarding the sequence for discontinuing co-therapy with a Beta-blocker. Official documentation specifies that the Beta-blocker should be discontinued first by your prescribing professional. Физиотенз is then stopped only after a period of a few days following the Beta-blocker's cessation.

---

Q: What are the most common side effects of Moxonidine?

Based on the official safety profile, dry mouth is the most frequently reported adverse reaction, classified as Very Common (≥ 1/10). Other commonly reported effects (≥ 1/100 to < 1/10) include headache, dizziness, somnolence (drowsiness), insomnia, and nausea.

---

Q: How long does it take for Moxonidine to start lowering my blood pressure after I start taking it?

Studies on the medication show that the maximum concentration of Moxonidine in the blood is typically reached between 30 minutes and 3 hours after administration. This time frame relates to the point of maximum concentration in the blood, which is associated with the onset of the medicine's activity.

---

Q: Can I crush the tablets to take them with food?

The official instructions for use state that the film-coated tablets must be swallowed whole with sufficient fluid. The tablets should not be chewed or crushed, as they are formulated to be swallowed whole to ensure the correct systemic delivery of the medicine.

---

Q: What is the main difference between Moxonidine and an older type of centrally acting agent like Clonidine?

Moxonidine is described in regulatory contexts as a second-generation centrally acting agent. Official data indicates it has a significantly greater affinity for the I1-Imidazoline receptor compared to the alpha2-adrenoceptors, which are the main target for some older central agents.

---

Q: What does the designation of I1-Imidazoline receptor agonist mean?

This designation means the medicine acts by selectively stimulating the I1-Imidazoline receptors located in the brainstem. The activation of these receptors is the key step that leads to a reduction in the central Sympathetic Nervous System (SNS) activity. This action promotes the relaxation of blood vessels and contributes to the lowering of systemic blood pressure.

How to Store and Dispose of Физиотенз?

This medication must be stored according to regulatory requirements to maintain its stability and effectiveness.

Storage Requirements

Condition	Requirement (Official Labeling)
Temperature Constraint	Store below 25 C in a cool dry place.
Protection	Keep in the original pack to protect from moisture, heat, and sunlight.
Stability	Do not use after the expiry date (EXP) printed on the carton.
Handling	Keep out of the sight and reach of children.

Disposal Instructions

Medicines should not be disposed of via wastewater or household waste. All unused, expired, or damaged product must be discarded in a manner that protects the environment, typically by returning it to a pharmacist for proper disposal according to local guidelines.